Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 176   

Articles published

VRX 31.20 -0.07 (-0.22%)
price chart
Valeant Pharmaceuticals International Inc sued for fraud by T. Rowe Price Group
T. Rowe Price Group Inc has sued Valeant Pharmaceuticals International Inc , alleging that investors in the Canadian drugmaker lost billions of dollars as a result of the company's “fraudulent scheme.
Valeant Pharmaceuticals Intl Inc (VRX): Guilty of Deceptive Practices – T ...  TCC
Canaccord Raises Price Target on Valeant Pharmaceuticals International, Inc ...  Smarter Analyst
Valeant Pharmaceuticals International Inc shares gain as once-burned analysts ...
Stock analysts are starting to come back around to Valeant Pharmaceuticals International Inc. after being burned by the company over the last year.
Lonestar Capital Raises New Stake in Valeant Pharmaceuticals International ...  TCC
If Valeant Pharmaceuticals Intl Inc Does THIS, VRX Stock Could Soar  Profit Confidential
Valeant Pharmaceuticals International Inc slides on report of U.S. criminal ...
Valeant Pharmaceuticals International Inc. fell 6.7 per cent following a report that it's the target of a criminal probe by federal prosecutors, who are investigating whether the drugmaker defrauded insurers by hiding its ties to a mail-order pharmacy.
Valeant Pharmaceuticals Intl Inc.: This Risky Stock Has Huge Upside  The Motley Fool Canada
The Biotech Round-Up: Valeant Pharmaceuticals Intl Inc, Inovio ...  Smarter Analyst
Valeant Pharmaceuticals International Inc maintains forecast, plans US$8 ...
LAVAL, Que. - Exactly a year ago Valeant Pharmaceuticals International Inc. was the largest company by market value on the Toronto Stock Exchange, a height it briefly stood before the share price came crashing down more than 90 per cent in a matter of ...
Valeant Pharmaceuticals Intl Inc (VRX): How Much Would Relistor Fetch in a ...  TCC
Canaccord Analysts Weigh In on Two Rising Stocks: Valeant Pharmaceuticals ...  Smarter Analyst
Valeant Pharmaceuticals Intl Inc Reveals Series of Executive Committee Changes
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced on Monday that Paul Herendeen, former Zoetis CFO and EVP will replace Robert Rosiello as the company's new CFO.
RBC Capital Positive on Valeant Pharmaceuticals Intl Inc New CFO Mr. Paul ...  TCC
Valeant Names Zoetis Executive as CFO  Wall Street Journal
Valeant Pharmaceuticals Intl Inc (VRX): Isn't A $55 PT Too Optimistic?
The recent appointment of Mr. Paul Herendeen as the new CFO of Valeant Pharmaceuticals Intl (NYSE:VRX) seems to be the trigger of the recent bullish wave.
Stock's Earning Overview: Valeant Pharmaceuticals International, Inc ...  News Oracle
Momentum Stocks: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Pfizer Inc ...  Post Registrar
Has Valeant Pharmaceuticals Intl Inc. Hit the Bottom Yet?
On this day last year Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) was flirting with a meteoric stock price of $347 per share.
Will Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Survive Under Papa's ...  TCC
Why This Analyst Thinks Valeant Pharmaceuticals Intl Inc Is Still Doomed  Smarter Analyst
Why This Analyst is Putting Valeant Pharmaceuticals Intl Inc (VRX) on the Back ...
Piper Jaffray analyst David Amsellem continues to sound the alarm on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), after the drug maker received permission from its lenders to renegotiate its agreement that will allow the company to produce trailing ...
Valeant Stock: Is it Time to Bail on Valeant Pharmaceuticals Intl Inc?
Valeant Pharmaceuticals International Inc (NYSE:VRX) has started climbing again, and what a climb it was! Valeant stock gained 21.69% after releasing earnings on August 8. Valeant stock has since taken a slight—but we expect temporary—beating over ...
Will Philidor Sink Valeant Pharmaceuticals Intl Inc's (VRX) Already ...  TCC
Most Recent analysts Ratings: Valeant Pharmaceuticals International, Inc ...  News Oracle
Valeant Pharmaceuticals Intl Inc (VRX): Here's What the Weekly Prescription ...
Douglas Meihm, RBC Capital analyst provided commentary on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) as he noted 1.5% decline in derm script performance for the week ended August 12.